ADO 5.26% 2.0¢ anteotech ltd

Ann: AnteoTech Progresses COVID-19 Test Toward Market Launch, page-524

  1. 48 Posts.
    lightbulb Created with Sketch. 21
    Atomo have non-exclusive rights to market and distribute Access Bio’s rapid antigen test (Atomo didn’t develop it) - the test has 88.4% sensitivity and is FDA and TGA approved.
 
watchlist Created with Sketch. Add ADO (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.